20 May 2024
20 May 2024
Senator Sanders took another swipe at the US prices of Novo Nordisk’s blockbuster GLP-1 receptor agonist drugs Ozempic and Wegovy.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
The jury found that AstraZeneca's Tagrisso violated Pfizer's Wyeth unit's patent rights.
J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.
Erasca has made operational cuts while licensing a molecular glue therapy and a KRAS inhibitor for $22.5m upfront.
The development comes after the regulator found increased cancer risk in people exposed to 17-OHPC.
With patients taking control over health, experts discuss how different players in the healthcare system are responding to the shifting relationship.
The NMPA's decision was based on the positive outcomes of the Phase III ATTACK trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
Give your business an edge with our leading industry insights.
